מיפג'ין

Pays: Israël

Langue: hébreu

Source: Ministry of Health

Ingrédients actifs:

MIFEPRISTONE

Disponible depuis:

A. LAPIDOT PHARMACEUTICALS, LTD

Code ATC:

G03XB01

forme pharmaceutique:

טבליה

Composition:

MIFEPRISTONE 200 MG

Mode d'administration:

פומי

Type d'ordonnance:

מרשם נדרש

Fabriqué par:

EXELGYNE LABORATORIES, FRANCE

Groupe thérapeutique:

MIFEPRISTONE

Domaine thérapeutique:

MIFEPRISTONE

indications thérapeutiques:

Medical alternative to uterine suction for termination of intra-utrerine Pregnancy: - up to and no later than 49 days of amenorrhea (seven weeks) - in sequential use with a prostaglandin analogue misoprostol 400 mcg per os administered 36 to 48 hours after Mifegyne intake. Under these conditions the association of mifepristone and prostaglandins leads to a success rate of about 95 per cent of the cases. Preparation for the action of prostaglandin analogues in the termination of pregnancy for medical reason (beyond the first trimester). Softening and dilatation of the cervix uteri prior to surgical termination of pregnancy during the first trimester.

Date de l'autorisation:

2014-07-31